Market Place
Sourcing Support
In8Bio Discloses Inducement Grant Per Nasdaq LR 5635(C)(4)
03 Apr 2026 //
GLOBENEWSWIRE
In8Bio Shows Strong 2025 Financials, Enhances Glioblastoma
12 Mar 2026 //
GLOBENEWSWIRE
In8Bio To Present At TD Cowen 46th Annual Health Care Conference
24 Feb 2026 //
GLOBENEWSWIRE
In8Bio Elevates Kate Rochlin, Ph.D., To President & Coo
09 Feb 2026 //
GLOBENEWSWIRE
IN8bio to Present at February Investor & Scientific Conferences
03 Feb 2026 //
GLOBENEWSWIRE
IN8Bio Shows Phase I/II Data With Significant Survival Gains
12 Jan 2026 //
GLOBENEWSWIRE
IN8bio Prices $40.2M for Its Gamma-Delta T Cell Engager
19 Dec 2025 //
GLOBENEWSWIRE
In8Bio Reveals Q3 2025 Financials & Business Updates
06 Nov 2025 //
GLOBENEWSWIRE
In8Bio Expands INB-100 Phase 1 Trial To Include Ohio Site
29 Oct 2025 //
GLOBENEWSWIRE
In8Bio Shows T Cell Engager Data For Autoimmune B Cell Depletion
27 Oct 2025 //
GLOBENEWSWIRE
In8bio Reports Q2 2025 Financial Results and Recent Business
07 Aug 2025 //
GLOBENEWSWIRE
IN8bio Acknowledges 4-Year Remission in Glioblastoma Trial
09 Jun 2025 //
GLOBENEWSWIRE
IN8bio Presents Preclinical Data on INB-619 TCE at ASGCT 2025
14 May 2025 //
GLOBENEWSWIRE
IN8bio Data at ISCT 2025 Shows γδ T Cell Manufacturing Success
12 May 2025 //
GLOBENEWSWIRE
IN8bio Reports Q1 2025 Financial Results and Business Highlights
07 May 2025 //
GLOBENEWSWIRE
IN8bio to Presents Gamma-Delta T Cell Platform at Conferernce
29 Apr 2025 //
GLOBENEWSWIRE
IN8bio Reveals New Data from Gamma-Delta TCE Platform at AACR 2025
28 Apr 2025 //
GLOBENEWSWIRE
IN8bio to Present New Preclinical Data on T cell Engager at Meeting
31 Mar 2025 //
GLOBENEWSWIRE
IN8bio Reports 2024 Financial Results and Business Highlights
13 Mar 2025 //
GLOBENEWSWIRE
IN8bio Unveils Gamma-Delta TCE Platform For Cancer, Autoimmune
03 Mar 2025 //
GLOBENEWSWIRE
IN8bio to Present at TD Cowen 45th Annual Health Care Conference
26 Feb 2025 //
GLOBENEWSWIRE
IN8bio to Present at H.C. Wainwright Cell Therapy Conference
24 Feb 2025 //
GLOBENEWSWIRE
IN8bio Highlights Durable Remissions In Ph1 High-Risk AML
14 Feb 2025 //
GLOBENEWSWIRE
IN8bio Reports Positive Results from Phase 1 Leukemia Trial
11 Feb 2025 //
GLOBENEWSWIRE
IN8bio to Present at Biotech Showcase 2025 in San Francisco
06 Jan 2025 //
GLOBENEWSWIRE
IN8bio Reports Progression-Free Survival For INB-100 In Leukemias
10 Dec 2024 //
GLOBENEWSWIRE
IN8bio to Present at 2024 SNO Annual Meeting
12 Nov 2024 //
GLOBENEWSWIRE
IN8bio Announces Presentation at ASH 2024 Annual Meeting
05 Nov 2024 //
GLOBENEWSWIRE
IN8bio Announces Pricing of $12.4 Million Private Placement
01 Oct 2024 //
GLOBENEWSWIRE
IN8bio Halts Ph 2 Glioblastoma Trial, Focuses on Leukemia Therapy After Layoffs
05 Sep 2024 //
FIERCE BIOTECH
IN8bio Prioritizes INB-100 For Acute Myeloid Leukemia
04 Sep 2024 //
GLOBENEWSWIRE
IN8bio Reports 100% AML Remission, FDA Guidance For INB-100 Trial
12 Aug 2024 //
GLOBENEWSWIRE
IN8bio Shows 100% 1-Year Complete Remission With INB-100 In Phase 1
13 Jun 2024 //
GLOBENEWSWIRE
IN8bio`s INB-200 Progression-Free Survival Update At ASCO 2024
03 Jun 2024 //
GLOBENEWSWIRE
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
24 May 2024 //
GLOBENEWSWIRE
In8bio Inb-200 Glioblastoma Data: Phase 1 Study At 2024 Asco
23 May 2024 //
GLOBENEWSWIRE
IN8bio Shows Robust Gamma-Delta T Cell Therapy Manufacturing At ASGCT 2024
13 May 2024 //
GLOBENEWSWIRE
IN8bio Doses First Patient in Ph2 INB-400 Newly Diagnosed GBM Trial
30 Apr 2024 //
GLOBENEWSWIRE
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy
14 Feb 2024 //
GLOBENEWSWIRE
IN8bio Announces Positive Update of Patients in Ph 1 of INB-100 in Leukemia
11 Dec 2023 //
GLOBENEWSWIRE
IN8bios INB-200 Demonstrates Extended Progression-Free Survival in Glioblastoma
20 Nov 2023 //
GLOBENEWSWIRE
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400
10 Nov 2023 //
GLOBENEWSWIRE
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial
06 Nov 2023 //
GLOBENEWSWIRE
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100
02 Nov 2023 //
GLOBENEWSWIRE
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100
12 Oct 2023 //
GLOBENEWSWIRE
IN8bio Announces Presentations at the SITC 38th Annual Meeting
29 Sep 2023 //
GLOBENEWSWIRE
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies
26 Sep 2023 //
GLOBENEWSWIRE
IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
20 Sep 2023 //
GLOBENEWSWIRE
IN8bio to Participate at H.C. Wainwright 25th Annual Global Conference
06 Sep 2023 //
GLOBENEWSWIRE
IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
15 Aug 2023 //
GLOBENEWSWIRE
IN8bio Expands Capabilities with the Grand Opening of R&D Facility
08 Aug 2023 //
GLOBENEWSWIRE
IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma
05 Jun 2023 //
GLOBENEWSWIRE
IN8bio`s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
17 May 2023 //
GLOBENEWSWIRE
IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in (GBM)
26 Apr 2023 //
GLOBENEWSWIRE
IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remission
24 Apr 2023 //
GLOBENEWSWIRE
IN8bio to Present Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT
11 Apr 2023 //
GLOBENEWSWIRE
IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals
05 Jan 2023 //
GLOBENEWSWIRE
IN8bio to Present at Biotech Showcase 2023 in San Francisco
03 Jan 2023 //
GLOBENEWSWIRE
